Max Healthcare Institute
Max Healthcare Institute runs a network of premium hospitals concentrated in Delhi NCR and North India, under sole promoter Abhay Soi.
- P/E ~60-70x
- Stock -34% from peak
- PAT fall is a tax base-effect
- NPPA oncology margin cap overhang
- Zero promoter pledge
Updated on 2 Nov 2026 · Data as of 30 Oct 2026
Get this report as a PDF free, straight to your inbox.
Snapshot
- Share price
- ₹860.00
- 30 Oct 2026
- 52-week range
- ₹815.00 – ₹1,179.00
- All-time peak
- ₹1,297.59
- 3 Jul 2025 · −33.7% from peak
- Dividend yield
- 0.23%
- Price history since
- 2020
- About 6 years of prices
What's happening
Max Healthcare reported Q2 FY27 (Sept 2026 quarter) results on Oct 30, 2026: consolidated revenue rose 20% YoY to ₹2,569 crore and EBITDA rose 24% to ₹712 crore (margin up to 27.7% from 26.9%), but reported net profit fell 15.6% YoY to ₹414 crore. Separately, reports of a proposed 30% NPPA trade-margin cap on 137 non-scheduled cancer drugs pulled the stock down roughly 20% over three weeks in October 2026, since oncology is close to a fifth of Max's revenue.
In plain terms
This is a hospital chain, not a pharma or insurance company - it earns from bed occupancy, surgeries, diagnostics and pharmacy sales within its own hospitals. The scary-looking '15.6% profit drop' headline is mostly a tax accounting artifact, not a business slowdown - last year's quarter had a one-off tax credit tied to a merger that didn't repeat. On the metric management itself uses (network PAT, including hospitals run under management contracts), profit actually grew 10%. The real live risk is a government price cap on cancer drug margins, which could structurally dent a meaningful slice of revenue going forward - that's separate from, and more durable than, this one quarter's tax noise.
Quarters
Revenue has risen steadily for five straight quarters: ₹2,135 cr (Q2 FY26) → ₹2,068 cr (Q3 FY26) → ₹2,143 cr (Q4 FY26) → ₹2,366 cr (Q1 FY27) → ₹2,569 cr (Q2 FY27). EBITDA has moved broadly in step, and EBITDA margin actually expanded this quarter. The one number that looks odd - PAT of ₹414 cr in Q2 FY27 versus ₹491 cr a year ago - is NOT comparable: the year-ago quarter carried a roughly ₹149 cr one-off tax benefit linked to the Crosslay Remedies/Jaypee Healthcare merger, which flipped tax expense from a ₹45 cr credit then to a ₹126 cr charge now. Strip that out and underlying (network-basis) PAT grew 10% YoY to ₹448 crore. Management flagged faster occupancy ramp-up on newly added beds and growing medical-value-travel (foreign patient) volumes as the drivers of the top-line growth.
Performance
Share price
−26.9% over 1 year
Returns by period
| Period | Max Healthcare Institute | Nifty 50 | Apollo Hospitals Enterprise |
|---|---|---|---|
| 3 months | −21.7% | −5.5% | −5.6% |
| 1 year | −26.9% | −10.9% | +8.7% |
| 3 years | +50.6% | +20.8% | +76.6% |
| 5 years | +152.5% | +28.6% | +97.5% |
₹100 invested on 1 Nov 2021 became…
- Max Healthcare Institute₹252
- Nifty 50₹129
- Apollo Hospitals Enterprise₹197
There have been no splits or demergers here (has_corporate_action: false), so the price series can be read at face value - this is a genuine, not an accounting-driven, move. The uncomfortable fact: the stock is down 33.7% from its July 2025 peak of ₹1,297.59 and is sitting near its 52-week low of ₹815, against a last close of ₹860. It has badly underperformed both the Nifty and its closest listed peer, Apollo Hospitals, over the last quarter (-21.7% vs Nifty -5.5% and peer -5.6%) and the last year (-26.9% vs Nifty -10.9% and peer +8.7%). Zoom out further, though, and the picture flips: over 5 years the stock has returned 152.5%, well ahead of both the Nifty (28.6%) and Apollo (97.5%) - so this is a strong long-term compounder that has given back a large chunk of recent gains, not a structural underperformer.
Dividend
Paid in the last 12 months
₹2.00 per share
Dividend yield
0.23%
Dividend yield is the last 12 months of dividends divided by today's share price. A 0.2% yield means every ₹100 of Max Healthcare Institute shares paid about ₹0.2 in dividends over the past year. Past payouts can change.
Recent dividends
| Date | Per share |
|---|---|
| 3 Jul 2026 | ₹2.00 |
| 4 Jul 2025 | ₹1.50 |
| 23 Aug 2024 | ₹1.50 |
| 8 Sept 2023 | ₹1.00 |
Valuation
The stock trades at a rich P/E of roughly 60-70x (figures vary slightly by source and date) and P/B of around 7.6-10x, against an ROE of about 14-15% and ROCE of roughly 13-15%. Why it commands this premium: Max is one of the few large, listed, pure-play premium hospital networks in India's most profitable healthcare market (Delhi NCR), with a scarce-asset quality and visible bed-capacity growth (+20% YoY) plus medical-tourism optionality. Whether that premium is justified is a separate question - a P/E multiple this far above the ROE it is currently generating is pricing in a lot of future growth, and the recent 34% drawdown shows the market is already re-rating that growth assumption down in response to the oncology margin-cap overhang.
Growth
This is growth that is both volume- and margin-led, the healthier combination: network gross revenue was up 20% YoY, driven by a 20% YoY increase in bed capacity (to 6,184 beds) with management citing faster-than-usual occupancy ramp-up on the new beds, while EBITDA margin simultaneously expanded (26.9% to 27.7%). Flat or margin-only growth would be a weaker signal; here the underlying volumes are expanding alongside profitability.
Health
On a network basis, EBITDA is converting into profit reasonably well - PAT grew 10% in step with margin expansion. The headline consolidated PAT decline this quarter is a tax/accounting base effect, not a cash-conversion problem. Debt stood at about ₹3,795 crore as of September 2026, being used to fund an active capex programme (₹415 crore just approved for ~209 new brownfield beds across MSSH Noida, MSSH Vaishali and BLK Max). At roughly 1.3x annualised EBITDA, leverage looks moderate rather than alarming. The bigger concern here is business/regulatory risk - the NPPA's proposed cancer-drug margin cap - rather than financial risk from the balance sheet.
Ownership
Abhay Soi is the sole promoter with a 23.71% stake as of September 2026, essentially flat versus 23.74% a year earlier, and promoter pledge stands at 0% - no leverage against the promoter's own holding. Institutional ownership is heavy (FIIs and DIIs together reported well over 50% of the register), though the individual category percentages sourced did not neatly reconcile to 100%, so treat the exact split with caution and verify on screener/BSE. No widely known individual retail investor could be confirmed on the register from available data.
The View
The one thing to watch
Q3 FY27 results will show whether network-basis PAT growth (~10% ex one-offs this quarter) holds up once the NPPA cancer-drug margin cap is finalised and takes effect - that will test whether the ~4% EPS-impact estimate is accurate or understates the hit.
Strengths
- +EBITDA margin expanded from 26.9% to 27.7% YoY in Q2 FY27 even while the network added capacity.
- +Bed capacity grew 20% YoY to 6,184 beds, with management citing faster occupancy ramp-up on new beds - a sign of real demand absorption, not just supply addition.
- +Zero promoter pledge and a stable ~23.7% promoter stake show no financial stress at the promoter level.
- +5-year shareholder return of 152.5% has comfortably beaten both the Nifty (28.6%) and peer Apollo Hospitals (97.5%).
Watchpoints
- !NPPA's proposed 30% trade-margin cap on 137 non-scheduled cancer drugs is estimated to hit Max's earnings by roughly 4% - oncology is close to a fifth of its revenue, a larger exposure than most peers.
- !Headline consolidated PAT fell 15.6% YoY in Q2 FY27 purely because a one-off tax credit in the year-ago quarter didn't repeat - a reminder to check tax-line notes before trusting any YoY PAT comparison from this company.
- !Stock is down 33.7% from its July 2025 peak and sitting near its 52-week low of ₹815, with sharp 3-month and 1-year underperformance versus both the Nifty and peer Apollo Hospitals.
- !Valuation remains rich (P/E ~60-70x, P/B ~7.6-10x) against a mid-teens ROE, leaving limited cushion if the oncology margin cap or further regulatory action compresses margins.
How sure are we about the data? · Moderate
Q2 FY27 consolidated revenue (₹2,569 cr) and PAT (₹414-415 cr) figures were consistent across Business Standard, Zeebiz and Screener.in; the separate 'network PAT' figure (₹448 cr, +10% YoY) comes from company commentary and is not strictly comparable to the consolidated PAT line - flagged explicitly above. Valuation multiples (P/E 60-74x, P/B 7.6-10x, ROCE 12.7-15%) varied by source and date, so screener.in's figures were used as the primary reference. Shareholding percentages sourced via search (promoter 23.71%, FII 21.27%, DII 31.00%, public 3.28%) did not sum to 100% and should be independently verified on screener/BSE before relying on the exact split. Could not verify whether any marquee individual investor holds a stake.
Keep it for later
Get the Max Healthcare Institute report as a PDF
The full report, neatly laid out with charts and tables, sent to your inbox. Handy to read offline or share.
Reports are refreshed every quarter, about three days after each company announces its results.
Ticker Tales is not a SEBI-registered investment adviser or research analyst. This report is for learning only and is not investment advice. Data as of 30 Oct 2026.